Leslie Chong Interview 3, page-24

Yes, Viralytics got taken out for $500m.

There's the PH connection, but also they were in the cancer immunology field.

Their drug helped two T cell therapy drugs, where as imu's technology appears to supersede T therapy drugs.

Viralytics was only really tempting for Merck or Bristol Myers. Imugene should be tempting to all pharmas. Not just because of the lead it will give them, but it's equally important that the competition doesn't get it - hence a bidding war could ensue.

I think those who make the first bid or deal has to make it big enough to stick.

cheers